Form 4: Jazz Pharma CCO Granted 9,782 Restricted Stock Units

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, was granted 9,782 restricted stock units, vesting over four years.

Summary

• Samantha Pearce, Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals plc, reported an acquisition of securities.
• The transaction involved the grant of 9,782 ordinary shares in the form of Restricted Stock Units (RSUs).
• The RSUs were granted on February 26, 2026, with a transaction price of $0.0, indicating a grant rather than a purchase.
• Following this transaction, Samantha Pearce beneficially owns 52,775 ordinary shares.
• These RSUs are part of the Issuer's 2011 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one ordinary share upon vesting.
• The units will vest in equal annual installments over four years, commencing from March 5, 2026, with 1/4th vesting on the first anniversary and the remainder vesting equally over the subsequent three years.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive indicator, reflecting ongoing executive compensation practices that align management's interests with long-term company performance and shareholder value.

Positives

• The grant of Restricted Stock Units aligns the executive's long-term interests with those of shareholders, incentivizing sustained company performance.
• The compensation structure, tied to future vesting, promotes executive retention and commitment to the company's strategic goals.

Negatives

• The RSUs do not represent immediate cash value or fully vested ownership, as they are subject to a multi-year vesting schedule.
• The ultimate value of the grant to the executive is dependent on the future market performance of Jazz Pharmaceuticals' ordinary shares.

Risks

• The value of the granted RSUs is subject to market fluctuations of Jazz Pharmaceuticals' ordinary shares.
• The executive must remain employed with the company through the vesting periods to realize the full benefit of the grant, posing a retention risk for the company if the executive departs prematurely.

Future Outlook

The grant of Restricted Stock Units implies a future increase in the executive's direct share ownership as the units vest over a four-year period, starting from March 5, 2026.

Industry Context

StockSavvy.ai notes that RSU grants are a common and widely accepted form of executive compensation in the pharmaceutical industry, designed to align executive incentives with long-term shareholder value creation and promote executive retention.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are standard practice for executive compensation across various industries, including pharmaceuticals, technology, and finance, serving as a key tool for talent retention and performance alignment.
• Companies like Pfizer, Merck, and Johnson & Johnson frequently utilize similar equity-based compensation plans for their senior executives, typically involving vesting periods of three to five years to ensure long-term commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with long-term shareholder value, potentially leading to more focused strategic decisions aimed at increasing stock price.
• Employees: This grant is part of the company's executive compensation strategy, which can influence overall compensation philosophy and morale within the organization.

Next Steps

• The granted Restricted Stock Units will begin vesting on March 5, 2026, with installments occurring annually over the subsequent four years.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Samantha Pearce, Equity Incentive Plan